The board of directors of Sino Biopharmaceutical Limited announced that an investigational new drug ("IND") application of the innovative medicine "TCR1672" self-developed by the Group has been filed with and accepted by the United States Food and Drug Administration ("FDA"). TCR1672 is a second-generation, highly selective P2X3 receptor antagonist mainly used in the treatment for adult patients with refractory chronic cough (RCC), and patients with complex visceral pain such as endometriosis pain. P2X3 receptor is a ligand-gated ion channel in the purine receptors family. Studies have shown that over-activation of P2X3 receptor is associated with hyper-sensitization of sensory neurons. Excessive, persistent and frequent coughs can be caused by injury or infection-induced hypersensitivity of airway and lung neurons. TCR1672 blocks the calcium ion influx from P2X3 receptor initiated by adenosine triphosphate (ATP), thereby exerting its specific inhibitory action to achieve therapeutic effect. To date, no P2X3 inhibitors have been approved in any country, and the related products have significant market potentials. The launch of the TCR1672 clinical trial will further enrich the Group's innovative product pipeline in the fields of respiratory diseases and analgesia, and bring new hope to patients.